Unmet needs in modern vaccinology. Adjuvants to improve the immune response

Vaccine

Volumn 28, Issue SUPPL. 3, 2010, Pages

  Leroux Roels, Geert ^a  

^a GHENT UNIVERSITY   (Belgium)

Author keywords

Adjuvants; Vaccines

Indexed keywords

ALUMINUM SALT; AREPANRIX; AVAXIN; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HEPATITIS B VACCINE; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DNA VACCINE; FLUVAL; HEMAGGLUTININ; HEPATITIS A VACCINE; HEPATITIS B VACCINE; IMIDAZOQUINOLINE DERIVATIVE; INFLUENZA VACCINE; LIPOSOME; LIVE VACCINE; MALARIA VACCINE; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; PANFLU; PANVAX; PEDIACEL; PENTACEL; PNEUMOCOCCUS VACCINE; PREPANRIX; QUINIVAXIN; RECOMBINANT HEPATITIS B VACCINE; SAPONIN DERIVATIVE; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG; VAXEMHIB; VIROSOME; WART VIRUS VACCINE; IMMUNOLOGICAL ADJUVANT; VACCINE;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTING CELL; CANCER IMMUNOTHERAPY; CROSS REACTION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EMULSION; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; IMMUNOSTIMULATION; INFLUENZA; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H5N1; INNATE IMMUNITY; MALARIA; MOLECULAR INTERACTION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SELF EVALUATION; VACCINATION; IMMUNOLOGY;

ADAPTIVE IMMUNITY; ADJUVANTS, IMMUNOLOGIC; HUMANS; IMMUNITY, INNATE; VACCINATION; VACCINES;

EID: 77955597687     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.07.021     Document Type: Review

References (107)

1. Zepp F. Principles of vaccine design-lessons from nature. Vaccine 2010, 28(Suppl 3):C14-C24.
2. World Malaria Report 2008. Available at 2008. http://www.who.int/malaria/wmr2008/malaria2008.pdf.
3. WHO, http://www.who.int/topics/influenza/en/.
4. WHO. Assessing the severity of an influenza pandemic. Accessed October, 2009.
5. Leroux-Roels I., Leroux-Roels G. Current status and progress of prepandemic and pandemic influenza vaccine development. Expert Rev Vaccines 2009, 8(4):401-423.
6. Aspinall R., Del Giudice G., Effros R.B., Grubeck-Loebenstein B., Sambhara S. Challenges for vaccination in the elderly. Immun Ageing 2007, 4:9.
7. Kawai T., Akira S. TLR signaling. Semin Immunol 2007, 19(1):24-32.
8. Moser M., Leo O. Key concepts in immunology. Vaccine 2010, 28(Suppl 3):C2-C13.
9. Ramon G. Sur la toxine et surranatoxine diptheriques. Ann Inst Pasteur 1924, (38):1-7.
10. Glenny A.T., Pope C.G., Waddington H., Wallace V. The antigenic value of toxoid precipitated by potassium-alum. J Path Bacteriol 1926, (29):38-45.
11. Garcon N., Chomez P., Van Mechelen M. GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives. Expert Rev Vaccines 2007, 6(5):723-739.
12. Reed S.G., Bertholet S., Coler R.N., Friede M. New horizons in adjuvants for vaccine development. Trends Immunol 2009, 30(1):23-32.
13. Tritto E., Mosca F., De Gregorio E. Mechanism of action of licensed vaccine adjuvants. Vaccine 2009, 27(25-26):3331-3334.
14. Allison A.C., Byars N.E. Immunological adjuvants: desirable properties and side-effects. Mol Immunol 1991, 28(3):279-284.
15. Brewer J.M. (How) do aluminium adjuvants work?. Immunol Lett 2006, 102(1):10-15.
16. Lindblad E.B. Aluminium adjuvants-in retrospect and prospect. Vaccine 2004, 22(27-28):3658-3668.
17. HogenEsch H. Mechanisms of stimulation of the immune response by aluminium adjuvants. Vaccine 2002, 20(Suppl 3):S34-S39.
18. Kool M., Soullie T., van Nimwegen M., Willart M.A., Muskens F., Jung S., et al. Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. J Exp Med 2008, 205(4):869-882.
19. Morefield G.L., Sokolovska A., Jiang D., HogenEsch H., Robinson J.P., Hem S.L. Role of aluminium-containing adjuvants in antigen internalization by dendritic cells in vitro. Vaccine 2005, 23(13):1588-1595.
20. Lambrecht B.N., Kool M., Willart M.A., Hammad H. Mechanism of action of clinically approved adjuvants. Curr Opin Immunol 2009, 21(1):23-29.
21. Aucouturier J., Dupuis L., Deville S., Ascarateil S., Ganne V. Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines. Expert Rev Vaccines 2002, 1(1):111-118.
22. Feyerabend S., Stevanovic S., Gouttefangeas C., Wernet D., Hennenlotter J., Bedke J., et al. Novel multi-peptide vaccination in Hla-A2+ hormone sensitive patients with biochemical relapse of prostate cancer. Prostate 2009, 69(9):917-927.
23. Leffers N., Lambeck A.J., Gooden M.J., Hoogeboom B.N., Wolf R., Hamming I.E., et al. Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial. Int J Cancer 2009, 125(9):2104-2113.
24. Barve M., Bender J., Senzer N., Cunningham C., Greco F.A., McCune D., et al. Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer. J Clin Oncol 2008, 26(27):4418-4425.
25. Garcia B., Neninger E., de la Torre A., Leonard I., Martinez R., Viada C., et al. Effective inhibition of the epidermal growth factor/epidermal growth factor receptor binding by anti-epidermal growth factor antibodies is related to better survival in advanced non-small-cell lung cancer patients treated with the epidermal growth factor cancer vaccine. Clin Cancer Res 2008, 14(3):840-846.
26. Neninger Vinageras E., de la Torre A., Osorio Rodriguez M., Catala Ferrer M., Bravo I., Mendoza del Pino M., et al. Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer. J Clin Oncol 2008, 26(9):1452-1458.
27. Podda A. The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine 2001, 19(17-19):2673-2680.
28. Baldo V., Baldovin T., Floreani A., Carraro A.M., Trivello R. MF59-adjuvanted influenza vaccine confers superior immunogenicity in adult subjects (18-60 years of age) with chronic diseases who are at risk of post-influenza complications. Vaccine 2007, 25(20):3955-3961.
29. Baldo V., Baldovin T., Floreani A., Fragapane E., Trivello R. Response of influenza vaccines against heterovariant influenza virus strains in adults with chronic diseases. J Clin Immunol 2007, 27(5):542-547.
30. Del Giudice G., Hilbert A.K., Bugarini R., Minutello A., Popova O., Toneatto D., et al. An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine. Vaccine 2006, 24(16):3063-3065.
31. Aguilar J.C., Rodriguez E.G. Vaccine adjuvants revisited. Vaccine 2007, 25(19):3752-3762.
32. Ambrosch F., Wiedermann G., Jonas S., Althaus B., Finkel B., Gluck R., et al. Immunogenicity and protectivity of a new liposomal hepatitis A vaccine. Vaccine 1997, 15(11):1209-1213.
33. Ben-Yehuda A., Joseph A., Barenholz Y., Zeira E., Even-Chen S., Louria-Hayon I., et al. Immunogenicity and safety of a novel IL-2-supplemented liposomal influenza vaccine (INFLUSOME-VAC) in nursing-home residents. Vaccine 2003, 21(23):3169-3178.
34. Ben-Yehuda A., Joseph A., Zeira E., Even-Chen S., Louria-Hayon I., Babai I., et al. Immunogenicity and safety of a novel liposomal influenza subunit vaccine (INFLUSOME-VAC) in young adults. J Med Virol 2003, 69(4):560-567.
35. Moser C., Amacker M., Kammer A.R., Rasi S., Westerfeld N., Zurbriggen R. Influenza virosomes as a combined vaccine carrier and adjuvant system for prophylactic and therapeutic immunizations. Expert Rev Vaccines 2007, 6(5):711-721.
36. Bovier P.A. Epaxal: a virosomal vaccine to prevent hepatitis A infection. Expert Rev Vaccines 2008, 7(8):1141-1150.
37. Bovier P.A. Recent advances with a virosomal hepatitis A vaccine. Expert Opin Biol Ther 2008, 8(8):1177-1185.
38. Bovier P.A., Farinelli T., Loutan L. Interchangeability and tolerability of a virosomal and an aluminium-adsorbed hepatitis A vaccine. Vaccine 2005, 23(19):2424-2429.
39. Holzer B.R., Hatz C., Schmidt-Sissolak D., Gluck R., Althaus B., Egger M. Immunogenicity and adverse effects of inactivated virosome versus alum-adsorbed hepatitis A vaccine: a randomized controlled trial. Vaccine 1996, 14(10):982-986.
40. Dagan R., Amir J., Livni G., Greenberg D., Abu-Abed J., Guy L., et al. Concomitant administration of a virosome-adjuvanted hepatitis a vaccine with routine childhood vaccines at age twelve to fifteen months: a randomized controlled trial. Pediatr Infect Dis J 2007, 26(9):787-793.
41. Herzog C., Hartmann K., Kunzi V., Kursteiner O., Mischler R., Lazar H., et al. Eleven years of Inflexal V-a virosomal adjuvanted influenza vaccine. Vaccine 2009, 27(33):4381-4387.
42. Kanra G., Marchisio P., Feiterna-Sperling C., Gaedicke G., Lazar H., Durrer P., et al. Comparison of immunogenicity and tolerability of a virosome-adjuvanted and a split influenza vaccine in children. Pediatr Infect Dis J 2004, 23(4):300-306.
43. Ruf B.R., Colberg K., Frick M., Preusche A. Open, randomized study to compare the immunogenicity and reactogenicity of an influenza split vaccine with an MF59-adjuvanted subunit vaccine and a virosome-based subunit vaccine in elderly. Infection 2004, 32(4):191-198.
44. Schaad U.B., Buhlmann U., Burger R., Ruedeberg A., Wilder-Smith A., Rutishauser M., et al. Comparison of immunogenicity and safety of a virosome influenza vaccine with those of a subunit influenza vaccine in pediatric patients with cystic fibrosis. Antimicrob Agents Chemother 2000, 44(5):1163-1167.
45. de Bruijn I., Meyer I., Gerez L., Nauta J., Giezeman K., Palache B. Antibody induction by virosomal, MF59-adjuvanted, or conventional influenza vaccines in the elderly. Vaccine 2007, 26(1):119-127.
46. de Bruijn I.A., Nauta J., Gerez L., Palache A.M. The virosomal influenza vaccine Invivac: immunogenicity and tolerability compared to an adjuvanted influenza vaccine (Fluad in elderly subjects). Vaccine 2006, 24(44-46):6629-6631.
47. Skeiky Y.A., Alderson M.R., Ovendale P.J., Guderian J.A., Brandt L., Dillon D.C., et al. Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein. J Immunol 2004, 172(12):7618-7628.
48. Ulrich J.T., Myers K.R. Monophosphoryl lipid A as an adjuvant, Past experiences and new directions. Pharm Biotechnol 1995, 6:495-524.
49. Evans J.T., Cluff C.W., Johnson D.A., Lacy M.J., Persing D.H., Baldridge J.R. Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi.529. Expert Rev Vaccines 2003, 2(2):219-229.
50. Didierlaurent A., Morel S., Lockman L., Giannini S., Bisteau M., Carlsen H., et al. AS04, an aluminium salt- and TLR4 agonist-based Adjuvant System induces a transient localized innate immune response leading to enhanced adaptive immunity. J Immunol 2009, 183(10):6186-6197.
51. Higgins D., Marshall J.D., Traquina P., Van Nest G., Livingston B.D. Immunostimulatory DNA as a vaccine adjuvant. Expert Rev Vaccines 2007, 6(5):747-759.
52. Zuber A.K., Brave A., Engstrom G., Zuber B., Ljungberg K., Fredriksson M., et al. Topical delivery of imiquimod to a mouse model as a novel adjuvant for human immunodeficiency virus (HIV) DNA. Vaccine 2004, 22(13-14):1791-1798.
53. Harrison C.J., Miller R.L., Bernstein D.I. Reduction of recurrent HSV disease using imiquimod alone or combined with a glycoprotein vaccine. Vaccine 2001, 19(13-14):1820-1826.
54. Johnston D., Zaidi B., Bystryn J.C. TLR7 imidazoquinoline ligand 3M-019 is a potent adjuvant for pure protein prototype vaccines. Cancer Immunol Immunother 2007, 56(8):1133-1141.
55. Garcon N., Heppner D.G., Cohen J. Development of RTS,S/AS02: a purified subunit-based malaria vaccine candidate formulated with a novel adjuvant. Expert Rev Vaccines 2003, 2(2):231-238.
56. Kensil C.R., Wu J.Y., Anderson C.A., Wheeler D.A., Amsden J. QS-21 and QS-7: purified saponin adjuvants. Dev Biol Stand 1998, 92:41-47.
57. Newman M.J., Wu J.Y., Gardner B.H., Anderson C.A., Kensil C.R., Recchia J., et al. Induction of cross-reactive cytotoxic T-lymphocyte responses specific for HIV-1 gp120 using saponin adjuvant (QS-21) supplemented subunit vaccine formulations. Vaccine 1997, 15(9):1001-1007.
58. Kim Y.J., Wang P., Navarro-Villalobos M., Rohde B.D., Derryberry J., Gin D.Y. Synthetic studies of complex immunostimulants from Quillaja saponaria: synthesis of the potent clinical immunoadjuvant QS-21Aapi. J Am Chem Soc 2006, 128(36):11906-11915.
59. Skene C.D., Sutton P. Saponin-adjuvanted particulate vaccines for clinical use. Methods 2006, 40(1):53-59.
60. Pearse M.J., Drane D. ISCOMATRIX adjuvant for antigen delivery. Adv Drug Deliv Rev 2005, 57(3):465-474.
61. Sun H.X., Xie Y., Ye Y.P. ISCOMs and ISCOMATRIX. Vaccine 2009, 27(33):4388-4401.
62. Sanders M.T., Deliyannis G., Pearse M.J., McNamara M.K., Brown L.E. Single dose intranasal immunization with ISCOMATRIX vaccines to elicit antibody-mediated clearance of influenza virus requires delivery to the lower respiratory tract. Vaccine 2009, 27(18):2475-2482.
63. Skene C.D., Doidge C., Sutton P. Evaluation of ISCOMATRIX and ISCOM vaccines for immunisation against Helicobacter pylori. Vaccine 2008, 26(31):3880-3884.
64. Drane D., Maraskovsky E., Gibson R., Mitchell S., Barnden M., Moskwa A., et al. Priming of CD4+ and CD8+ T cell responses using a HCV core ISCOMATRIX vaccine: a phase I study in healthy volunteers. Hum Vaccine 2009, 5(3):151-157.
65. Ebert L.M., Liu Y.C., Clements C.S., Robson N.C., Jackson H.M., Markby J.L., et al. A long, naturally presented immunodominant epitope from NY-ESO-1 tumor antigen: implications for cancer vaccine design. Cancer Res 2009, 69(3):1046-1054.
66. Middleton D., Rockman S., Pearse M., Barr I., Lowther S., Klippel J., et al. Evaluation of vaccines for H5N1 influenza virus in ferrets reveals the potential for protective single-shot immunization. J Virol 2009, 83(15):7770-7778.
67. Stewart V.A., McGrath S.M., Walsh D.S., Davis S., Hess A.S., Ware L.A., et al. Pre-clinical evaluation of new adjuvant formulations to improve the immunogenicity of the malaria vaccine RTS,S/AS02A. Vaccine 2006, 24(42-43):6483-6492.
68. Kruit W.H., Suciu S., Dreno B., Chiarion-Sileni V., Mortier L., Robert C., et al. Immunization with recombinant MAGE-A3 protein combined with adjuvant systems AS15 or AS02 in patients with unresectable and progressive metastatic cutaneous melanoma: A randomized open label phase II study of the EORTC Melanoma Group (16032-18031). J Clin Oncol 2008, 26(May 20 suppl; abstr 9065).
69. Vekemans J., Ballou W.R. Malaria vaccines in development. Expert Rev Vaccines 2008, 7(2):223-240.
70. Stoute J.A., Slaoui M., Heppner D.G., Momin P., Kester K.E., Desmons P., et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. N Engl J Med 1997, 336(2):86-91.
71. Bojang K.A., Milligan P.J., Pinder M., Vigneron L., Alloueche A., Kester K.E., et al. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet 2001, 358(9297):1927-1934.
72. Alonso P.L., Sacarlal J., Aponte J.J., Leach A., Macete E., Aide P., et al. Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial. Lancet 2005, 366(9502):2012-2018.
73. Alonso P.L., Sacarlal J., Aponte J.J., Leach A., Macete E., Milman J., et al. Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet 2004, 364(9443):1411-1420.
74. Aponte J.J., Aide P., Renom M., Mandomando I., Bassat Q., Sacarlal J., et al. Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial. Lancet 2007, 370(9598):1543-1551.
75. Kester K.E., Cummings J.F., Ofori-Anyinam O., Ockenhouse C.F., Krzych U., Moris P., et al. Randomized, double-blind, phase 2a trial of Falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in Malaria-Naive Adults: Safety, Efficacy, and Immunologic Associates of Protection. J Infect Dis 2009, 200(3):337-346.
76. Polhemus M.E., Remich S.A., Ogutu B.R., Waitumbi J.N., Otieno L., Apollo S., et al. Evaluation of RTS,S/AS02A and RTS,S/AS01B in adults in a high malaria transmission area. PLoS One 2009, 4(7):e6465.
77. Bejon P., Lusingu J., Olotu A., Leach A., Lievens M., Vekemans J., et al. Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. N Engl J Med 2008, 359(24):2521-2532.
78. Leroux-Roels I., Borkowski A., Vanwolleghem T., Drame M., Clement F., Hons E., et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 2007, 370(9587):580-589.
79. Ballester M., Garcés Sánchez M.V., Plannelles Cantarino M., Dramé J., Thonnard N., Bouveret P., et al. Safety evaluation of an AS-adjuvanted H5N1 prepandemic candidate vaccine in children aged 3 to 9 years. A phase II study. 13th international congress on infectious diseases 2008.
80. Moris P., Roman F., Diez-Domingo J., Van Mechelen M. Two primary vaccinations with an AS03-adjuvanted H5N1 prepandemic candidate vaccine in children aged 3-5 years induce high frequency of CD4 T-helper cells producing IL-2 and/or IFNγ. XI International Symposium on Respiratory Viral Infections 2009.
81. Heijmans S., De Meulemeester M., Reynders P., Giet D., Calozet Y., Demanet E., et al. AS03 adjuvanted prepandemic influenza vaccine: high immunogenicity in the elderly. Vaccine Congress - 2nd 2008.
82. Leroux-Roels I., Bernhard R., Gerard P., Drame M., Hanon E., Leroux-Roels G. Broad Clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine. PLoS ONE 2008, 3(2):e1665.
83. Baras B., Stittelaar K.J., Simon J.H., Thoolen R.J., Mossman S.P., Pistoor F.H., et al. Cross-protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine. PLoS ONE 2008, 3(1):e1401.
84. Schwarz T.F., Horacek T., Knuf M., Damman H.G., Roman F., Drame M., et al. Single dose vaccination with AS03-adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccination in adults. Vaccine 2009, 27(45):6284-6290.
85. Rumke H.C., Bayas J.M., de Juanes J.R., Caso C., Richardus J.H., Campins M., et al. Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial. Vaccine 2008, 26(19):2378-2388.
86. Aw D., Silva A.B., Palmer D.B. Immunosenescence: emerging challenges for an ageing population. Immunology 2007, 120(4):435-446.
87. Grubeck-Loebenstein B., Wick G. The aging of the immune system. Adv Immunol 2002, 80:243-284.
88. Targonski P.V., Jacobson R.M., Poland G.A. Immunosenescence: role and measurement in influenza vaccine response among the elderly. Vaccine 2007, 25(16):3066-3069.
89. De Donato S., Granoff D., Minutello M., Lecchi G., Faccini M., Agnello M., et al. Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly. Vaccine 1999, 17(23-24):3094-3101.
90. Leroux-Roels I, Moris P, Drame M, Clement F, Hons E, Vanwolleghem T, et al. Cross-Reactive humoral and cell-mediated immunity with an adjuvanted H5N1 candidate vaccine. WCOCI;2007.
91. Leroux-Roels I., Clement F., Leroux-Roels G., Dramé M., Moris P., Devaster J.M., et al. Adjuvanted influenza vaccines improve anti-influenza cellular mediated immunity impaired in elderly. 2nd international conference IVW 2006.
92. Leroux-Roels I., Clément F., Dramé M., Moris P., Devaster J.M., Leroux-Roels G. Adjuvanted influenza vaccines improve ant-influenza immune response altered in elderly. IX Annual Meeting ISRVI 2007.
93. Girndt M., Kohler H., Hepatitis B virus infection in hemodialysis patients. Semin Nephrol 2002, 22(4):340-350.
94. Zacks S.L., Fried M.W., Hepatitis B. C and renal failure. Infect Dis Clin North Am 2001, 15(3):877-899.
95. Boland G., Beran J., Lievens M., Sasadeusz J., Dentico P., Nothdurft H., et al. Safety and immunogenicity profile of an experimental hepatitis B vaccine adjuvanted with AS04. Vaccine 2004, 23(3):316-320.
96. Thoelen S., De Clercq N., Tornieporth N. A prophylactic hepatitis B vaccine with a novel adjuvant system. Vaccine 2001, 19(17-19):2400-2403.
97. Tong N.K., Beran J., Kee S.A., Miguel J.L., Sanchez C., Bayas J.M., et al. Immunogenicity and safety of an adjuvanted hepatitis B vaccine in pre-hemodialysis and hemodialysis patients. Kidney Int 2005, 68(5):2298-2303.
98. Kundi M. New hepatitis B vaccine formulated with an improved adjuvant system. Expert Rev Vaccines 2007, 6(2):133-140.
99. Stephenson I., Nicholson K.G., Hoschler K., Zambon M.C., Hancock K., DeVos J., et al. Antigenically distinct MF59-adjuvanted vaccine to boost immunity to H5N1. N Engl J Med 2008, 359(15):1631-1633.
100. Martin J.T. Development of an adjuvant to enhance the immune response to influenza vaccine in the elderly. Biologicals 1997, 25(2):209-213.
101. Ambrosch F., Finkel B., Herzog C., Koren A., Kollaritsch H. Rapid antibody response after vaccination with a virosomal hepatitis a vaccine. Infection 2004, 32(3):149-152.
102. Van Der Wielen M., Vertruyen A., Froesner G., Ibanez R., Hunt M., Herzog C., et al. Immunogenicity and safety of a pediatric dose of a virosome-adjuvanted hepatitis A vaccine: a controlled trial in children aged 1-16 years. Pediatr Infect Dis J 2007, 26(8):705-710.
103. Jacques P., Moens G., Desombere I., Dewijngaert J., Leroux-Roels G., Wettendorff M., et al. The immunogenicity and reactogenicity profile of a candidate hepatitis B vaccine in an adult vaccine non-responder population. Vaccine 2002, 20(31-32):3644-3649.
104. Stanberry L.R., Spruance S.L., Cunningham A.L., Bernstein D.I., Mindel A., Sacks S., et al. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med 2002, 347(21):1652-1661.
105. Verstraeten T., Descamps D., David M.P., Zahaf T., Hardt K., Izurieta P., et al. Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines. Vaccine 2008, 26(51):6630-6638.
106. Sesardic D., Rijpkema S., Patel B.P. New adjuvants: EU regulatory developments. Expert Rev Vaccines 2007, 6(5):849-861.
107. Brichard V.G., Lejeune D. Cancer immunotherapy targeting tumour-specific antigens: towards a new therapy for minimal residual disease. Expert Opin Biol Ther 2008, 8(7):951-968.